752 related articles for article (PubMed ID: 11129646)
1. DNA vaccination: antigen presentation and the induction of immunity.
Shedlock DJ; Weiner DB
J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines--challenges in delivery.
Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
[TBL] [Abstract][Full Text] [Related]
3. New tools for antigen delivery to the MHC class I pathway.
Morón G; Dadaglio G; Leclerc C
Trends Immunol; 2004 Feb; 25(2):92-7. PubMed ID: 15102368
[TBL] [Abstract][Full Text] [Related]
4. Targeting dendritic cells to enhance DNA vaccine potency.
You Z; Huang X; Hester J; Toh HC; Chen SY
Cancer Res; 2001 May; 61(9):3704-11. PubMed ID: 11325842
[TBL] [Abstract][Full Text] [Related]
5. Modifying professional antigen-presenting cells to enhance DNA vaccine potency.
Hung CF; Yang M; Wu TC
Methods Mol Med; 2006; 127():199-220. PubMed ID: 16988456
[TBL] [Abstract][Full Text] [Related]
6. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
7. Virosomes for antigen and DNA delivery.
Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
[TBL] [Abstract][Full Text] [Related]
8. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
9. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
Dobaño C; Rogers WO; Gowda K; Doolan DL
Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
[TBL] [Abstract][Full Text] [Related]
10. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
[TBL] [Abstract][Full Text] [Related]
11. The processing of antigens delivered as DNA vaccines.
Howarth M; Elliott T
Immunol Rev; 2004 Jun; 199():27-39. PubMed ID: 15233724
[TBL] [Abstract][Full Text] [Related]
12. Cross-presentation: underlying mechanisms and role in immune surveillance.
Rock KL; Shen L
Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
[TBL] [Abstract][Full Text] [Related]
13. Improving DNA vaccine potency via modification of professional antigen presenting cells.
Hung CF; Wu TC
Curr Opin Mol Ther; 2003 Feb; 5(1):20-4. PubMed ID: 12669466
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
16. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
17. Modulating the immune response to genetic immunization.
Cohen AD; Boyer JD; Weiner DB
FASEB J; 1998 Dec; 12(15):1611-26. PubMed ID: 9837851
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
19. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
